Gonzalo Guevara1, Jaime A González2, Diego E Lopera3, Manuel González4, José D Saavedra5, José Fernando Lobaton6, Jorge Enrique Duque7. 1. Instituto Colombiano de Genética y Oncologia Molecular E-mail: incogem@yahoo.com. 2. Oncologos de Occidente, Armenia, Colombia. E-mail: jaimegonzalezdiaz@hotmail.com. 3. Oncologos de Occidente, Manizales, Colombia. 4. Instituto Medico de Alta Tecnologia (IMAT), Monteria, Colombia. E-mail: Manuel101@gmail.com. 5. Clinica Vida, Medellin, Colombia E-mail: isaavedra@une.net.co. 6. Hospital Militar Central, Bogota, Colombia. E-mail: lobatonjf@yahoo.es. 7. Oncologos Asociados de Imbanaco, Cali, Colombia. E-mail: jorgeduque@telesat.com.co.
Abstract
OBJECTIVE: To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib. METHODS: Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months. RESULTS: The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response. CONCLUSIONS: Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies.
OBJECTIVE: To evaluate the hematological, cytogenetic, and molecular responses in Colombian patients with CML chronic myeloid leukemia (CML) treated with imatinib. METHODS: Two groups of patients, one with the novo diagnostic and another in state of complete cytogenetic remission were followed for 12 months with quantitative PCR evaluations every three months and with chromosomal analysis every 6 months. RESULTS: The group with the novo diagnosis showed 50% of complete cytogenetic remission at 12 months while the other 50% were considered to have primary resistance. Respect the molecular analysis, 10.5% of the patients reached undetectable BCR-ABL transcripts at 12 months. In the complete cytogenetic remission group, 10.6% lost the state of complete cytogenetic remission at 12 months, 50% reached undetectable BCR-ABL transcripts but 10% showed levels higher than 10%, which in our standardization was equal to no molecular response. CONCLUSIONS: Despite having received the conventional dosages of 400 mg/day of imatinib, the cytogenetic and molecular responses obtained in our group of Colombian patients with CML, were lower than those in other international studies.
Entities:
Keywords:
BCR-ABL; Philadelphia chromosome; imatinib; minimal residual disease
Authors: D Marin; J Kaeda; R Szydlo; S Saunders; A Fleming; J Howard; C Andreasson; M Bua; E Olavarria; A Rahemtulla; F Dazzi; E Kanfer; J M Goldman; J F Apperley Journal: Leukemia Date: 2005-04 Impact factor: 11.528
Authors: Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra Journal: N Engl J Med Date: 2002-02-28 Impact factor: 91.245
Authors: J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen Journal: Leukemia Date: 2003-12 Impact factor: 11.528
Authors: C Terre; V Eclache; P Rousselot; M Imbert; C Charrin; C Gervais; M J Mozziconacci; O Maarek; H Mossafa; N Auger; N Dastugue; P Talmant; J Van den Akker; C Leonard; F N'Guyen Khac; F Mugneret; F Viguié; M Lafage-Pochitaloff; J N Bastie; G L Roux; F Nicolini; F Maloisel; N Vey; G Laurent; C Recher; M Vigier; Y Yacouben; S Giraudier; J P Vernant; B Salles; J Roussi; S Castaigne; V Leymarie; G Flandrin; M Lessard Journal: Leukemia Date: 2004-08 Impact factor: 11.528
Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245